Contribution of germline BRCA1 and BRCA2sequence alterations to breast cancer in Northern India
Tóm tắt
A large number of distinct mutations in the BRCA1 and BRCA2 genes have been reported worldwide, but little is known regarding the role of these inherited susceptibility genes in breast cancer risk among Indian women. We investigated the distribution and the nature of BRCA1 and BRCA2 germline mutations and polymorphisms in a cohort of 204 Indian breast cancer patients and 140 age-matched controls. Cases were selected with regard to early onset disease (≤40 years) and family history of breast and ovarian cancer. Two hundred four breast cancer cases along with 140 age-matched controls were analyzed for mutations. All coding regions and exon-intron boundaries of the BRCA1 and BRCA2 genes were screened by heteroduplex analysis followed by direct sequencing of detected variants. In total, 18 genetic alterations were identified. Three deleterious frame-shift mutations (185delAG in exon 2; 4184del4 and 3596del4 in exon 11) were identified in BRCA1, along with one missense mutation (K1667R), one 5'UTR alteration (22C>G), three intronic variants (IVS10-12delG, IVS13+2T>C, IVS7+38T>C) and one silent substitution (5154C>T). Similarly three pathogenic protein-truncating mutations (6376insAA in exon 11, 8576insC in exon19, and 9999delA in exon 27) along with one missense mutation (A2951T), four intronic alterations (IVS2+90T>A, IVS7+75A>T, IVS8+56C>T, IVS25+58insG) and one silent substitution (1593A>G) were identified in BRCA2. Four previously reported polymorphisms (K1183R, S1613G, and M1652I in BRCA1, and 7470A>G in BRCA2) were detected in both controls and breast cancer patients. Rare BRCA1/2 sequence alterations were observed in 15 out of 105 (14.2%) early-onset cases without family history and 11.7% (4/34) breast cancer cases with family history. Of these, six were pathogenic protein truncating mutations. In addition, several variants of uncertain clinical significance were identified. Among these are two missense variants, one alteration of a consensus splice donor sequence, and a variant that potentially disrupts translational initiation.
BRCA1 and BRCA2 mutations appear to account for a lower proportion of breast cancer patients at increased risk of harboring such mutations in Northern India (6/204, 2.9%) than has been reported in other populations. However, given the limited extent of reported family history among these patients, the observed mutation frequency is not dissimilar from that reported in other cohorts of early onset breast cancer patients. Several of the identified mutations are unique and novel to Indian patients.
Tài liệu tham khảo
Parkin DM, Bray F, Ferlay J, Pisani P: Global CancerStatistics, 2002. CA Cancer J Clin. 2005, 55: 74-108.
GLOBOCAN 2002, IARC. [http://www.sunmed.org/incidence.html]
Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, eds: Cancer incidence in five Continents. 1997, Lyon: IARC. (IARC Scientific Publications 143), VIII:
National Cancer Registry Programme: Ten year consolidated report of the Hospital Based Cancer Registries, 1984–1993, An assessment of the burden and care of cancer patients. 2001, Indian Counsil of Medical Research, New Delhi. India
Consolidated report of the population based cancer registries. 2001, Indian Counsil of Medical Research, NCRP [National Cancer Registry Programme]. New Delhi, 1990-6.
Parkin DM, Whelann SL, Ferlay J, Teppo L, Thomas DB, eds: International Agency for research on cancer [IARC], Cancer Incidence in Five Continents. Lyon, France, [Eds] IARC (Scientific Publication 2002 No.155), VIII:
Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC: Linkage of early-onset familial breast cancer to chromosome17q21. Science. 1990, 250: 1684-1689. 10.1126/science.2270482.
Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994, 265: 2088-90. 10.1126/science.8091231.
Scully R, Livingston DM: In Search of the tomour-supperssor function of BRCA1and BRCA2. Nature. 2000, 408: 429-432. 10.1038/35044000.
Scully R, Puget N, Vlasakova K: DNA polymerase stalling, sister chromatid recombination and the BRCA genes. Oncogenes. 2000, 19: 6176-6183. 10.1038/sj.onc.1203971.
Wang Q, Zhang H, Fishel R, Greene MI: BRCA1 and cell signaling. Oncogene. 2000, 19: 6152-6158. 10.1038/sj.onc.1203974.
Zhang L, Li S, Boyer TG, Lee WH: Lessons learned from BRCA1 and BRCA2. Oncogene. 2000, 19: 6159-6175. 10.1038/sj.onc.1203968.
Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, Chen PL, Sharp ZD, Lee WH: Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science. 1999, 285: 747-750. 10.1126/science.285.5428.747.
Welcsh Piri, King Mary-Claire: BRCA1 and BRCA2 and genetics of breast and ovarian cancer. Human Molecular Genetics. 2001, 10: 7705-713. 10.1093/hmg/10.7.705.
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994, 266: 66-71. 10.1126/science.7545954.
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G: Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995, 378: 789-92. 10.1038/378789a0.
Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Goldgar DE: The complete BRCA2 gene and mutations in chromosome13q-linked kindreds. Nat Genet. 1996, 12: 333-7. 10.1038/ng0396-333.
1996, [http://research.nhgri.nih.gov/bic/]
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998, 62: 676-89. 10.1086/301749.
Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE: Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994, 343: 692-5. 10.1016/S0140-6736(94)91578-4.
Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003, 72: 1117-30. 10.1086/375033.
Genetic Testing for BRCA1 and BRCA2: It's Your Choice Cancer Facts 2/6/2002. [http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA]
Thompson D, Easton DF, Breast Cancer Linkage Consortium: Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002, 94: 1358-65.
The Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999, 91: 1310-1316. 10.1093/jnci/91.15.1310.
Szabo CI, King MC: Population genetics of BRCA1 and BRCA2. Am J Hum Genet. 1997, 60: 1013-20.
Kumar BV, Lakhotia S, Ankathil R, Madhavan J, Jayaprakash PG, Nair MK, Somasundaram K: Germline BRCA1 mutation analysis in Indian Breast/Ovarian cancer families. Cancer Biol Ther. 2002, 1 (1): 18-21.
Saxena S, Szabo C, Chopin S, Barjhoux L, Sinilnikova O, Lenoir G, Goldgar DE, Bhatnagar D: BRCA1 and BRCA2 in Indian Breast Cancer Patients. Human Mutation. 2002, 20 (6): 473-474. 10.1002/humu.9082.
Valarmathi MTAA, Deo SS, Shukla NK, Das SN: BRCA1 germline mutations in Indian familial breast cancer. Hum Mutat. 2003, 21: 98-9. 10.1002/humu.9099.
Valarmathi MT, Sawhney M, Suryanarayana SV, Deo SS, Shukla NK, Das SN: Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families. Hum Mutat. 2004, 23: 205-10.1002/humu.9213.
Hedau S, Jain N, Syed A, Husain , Das BC: Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. Breast Cancer Research and Treatment. 2004, 88: 177-186. 10.1007/s10549-004-0593-8.
Serova OM, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart YY, Goldgar D, Narod SA, Lynch HT, Lenoir GM: Mutations in BRCA1 and BRCA2 in breast cancer families: Are there more breast cancer susceptibility genes?. Am J Hum Genet. 1997, 60: 1013-20.
Saxena S, Rekhi B, Bansal A, Bagga A, Chintamani , Murthy NS: Clinico-morphological patterns of breast cancer including family history in a New Delhi hospital, India – a cross-sectional study. World J Surg Oncol. 2005, 3: 67-10.1186/1477-7819-3-67.
Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC: The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet. 1995, 11: 198-200. 10.1038/ng1095-198.
Neuhausen SL, Mazoyer S, Friedman LS, Stratton M, Offit K, Caligo A, Tomlinson G, Cannon-Albright L, Bishop T, Kelsell D, Solomon E, Weber B, Couch F, Struewing J, Tonin P, Durocher F, Narod S, Skolnick M, Lenoir G, Serova O, Ponder B, Stoppa-Lyonnet D, Easton D, King MC, Goldgar DE: Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an International study. Am J Hum Genet. 1996, 58: 271-280.
Bar-Sade RB, Kruglikova A, Modan B, Gak E, Hirsh-Yechezkel G, Theodor L, Novikov I, Gershoni-Baruch R, Risel S, Papa MZ, Ben-Baruch G, Friedman E: The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. Human Molecular Genetics. 1998, 7: 801-805. 10.1093/hmg/7.5.801.
Lakhotia , Somasundaram : Conformation Sensitive Gel Electrophoresis for detecting BRCA1 mutations. Methods in Molecular Biology. 2003, 223: 403-414.
Xu CF, Chambers JA, Nicolai H, Brown MA, Hujeirat Y, Mohammed S, Hodgson S, Kelsell DP, Spurr NK, Bishop DT, Solomon E: Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families. Genes Chromosomes Cancer. 1997, 18: 102-10. 10.1002/(SICI)1098-2264(199702)18:2<102::AID-GCC4>3.0.CO;2-6.
Stuppia L, Di Fulvio P, Aceto G, Pintor S, Veschi S, Gatta V, Colosimo A, Cianchetti E, Cama A, Mariani-Costantini R, Battista P, Palka G: BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy. Human Mutation. 2003, 22: 178-179. 10.1002/humu.9164.
Chapman MS, Verrma IM: Transcriptional activation by BRCA1. Nature. 1996, 382: 678-679. 10.1038/382678a0.
Monterio ANA, August A, Hanafusa H: Evidence of a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA. 1996, 93: 13595-13599. 10.1073/pnas.93.24.13595.
Liede A, Malik IA, Aziz Z, Rios P, Kwan E, Narod SA: Contribution of BRCA1 and BRCA2 Mutations to Breast and Ovarian Cancer in Pakistan. Am J Hum Genet. 2002, 71 (3): 595-606. 10.1086/342506.
Evan DGR, Nauhausen , Bulman M, Young K, Gokhale D, Lalloo F: Haplotype and cancer risk analysis of two common mutations, BRCA1 4184del4 and BRCA2 2157delG, in high risk northwest England breast/ovarian families. J Med genet. 2004, 41: e21-10.1136/jmg.2003.012104.
Bork P, Blomberg N, Nilges M: Internal repeats in BRCA2 protein sequence. Nat Genet. 1996, 13: 22-23. 10.1038/ng0596-22.
Wagner TMU, Hirtenlehner K, Shen P, Moeslinger R, Muhr D, Fleischmann E, Concin H, Doeller W, Haid A, Lang AH, Mayer P, Petru E, Ropp E, Langbauer G, Kubista E, Scheiner O, Underhill P, Mountain J, Stierer M, Zielinski C, Oefner P: Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations. Hum Mol Genet. 1999, 8: 413-23. 10.1093/hmg/8.3.413.
Zhang H, Somasundaram K, Peng Y: BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene. 1998, 16: 1713-1721.39. 10.1038/sj.onc.1201932.
Monteiro ANA, August A, Hanafusa H: Common BRCA1 variants and transcriptional activation. Am J Hum Genet. 1997, 61: 761-762.
Balraj P, Khoo ASB, Volpi L, Tan JA, Nair S, Abdullah H: Mutation analysis of the BRCA1 gene in Malaysian breast cancer patients. Singapore Med J. 2002, 43 (4): 194-197.
De Leon Matsuda M, Liede A, Kwan E, Mapua CA, Cutiongco EM, Tan A, Borg A, Narod SA: BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines. Int J Cancer. 2002, 98: 596-603. 10.1002/ijc.10194.
Suter NM, Ray RM, Hu YW, Lin MG, Porter P, Gao DL, Zaucha RE, Iwasaki LM, Sabacan LP, Langlois MC, Thomas DB, Ostrander EA: BRCA1 and BRCA2 mutations in women from Shanghai China. Cancer Epidemiol Biomarkers Prev. 2004, 13: 181-9. 10.1158/1055-9965.EPI-03-0196.
Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999, 91: 943-9. 10.1093/jnci/91.11.943.
Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro ANA, Tavitgian SV: Integrated evaluation of DNA sequence Variants of Unknown Clinical Significance: Application to BRCA1 and BRCA2. Am J Hum Genet. 2004, 75: 535-544. 10.1086/424388.
Eng C, Brody LC, Wagner TM, Devilee P, Vijg J, Szabo C, Tavtigian SV, Nathanson KL, Ostrander E, Frank TS, Steering Committee of the Breast Cancer Information Core (BIC) Consortium: Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Gene. 2001, 38: 824-33. 10.1136/jmg.38.12.824.
Puget N, Stoppa-Lyonnet D, Sinilnikova OM, Pages S, Lynch HT, Lenoir GM, Mazoyer S: Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer Res. 1999, 59: 455-61.
Unger MA, Nathanson KL, Calzone K, Antin-Ozerkis D, Shih HA, Martin AM, Lenoir GM, Mazoyer S, Weber BL: Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet. 2000, 67: 841-50. 10.1086/303076.
Montagna M, Dalla Palma M, Menin C, Agata S, De Nicolo A, Chieco-Bianchi L, D'Andrea E: Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families. Hum Mol Genet. 2003, 12: 1055-61. 10.1093/hmg/ddg120.
Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, Kluijt I, Dommering C, Verhoef S, Schouten JP, van't Veer LJ, Pals G: Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res. 2003, 63: 1449-53.
Hartmann C, John AL, Klaes R, Hofmann W, Bielen R, Koehler R, Janssen B, Bartram CR, Arnold N, Zschocke J: Large BRCA1 gene deletions are found in 3% of German high-risk breast cancer families. Hum Mutat. 2004, 24: 534-10.1002/humu.9291.
Tournier I, Paillerets BB, Sobol H, Stoppa-Lyonnet D, Lidereau R, Barrois M, Mazoyer S, Coulet F, Hardouin A, Chompret A, Lortholary A, Chappuis P, Bourdon V, Bonadona V, Maugard C, Gilbert B, Nogues C, Frébourg T, Tosi M: Significant contribution of germline BRCA2 rearrangements in male breast cancer families. Cancer Res. 2004, 64: 8143-7. 10.1158/0008-5472.CAN-04-2467.
Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC: Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006, 295: 1379-88. 10.1001/jama.295.12.1379.
Yassaee VR, Zeinali S, Harirchi I, Jarvandi S, Mohagheghi MA, Hornby DP, Dalton A: Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer. Breast Cancer Res. 2002, 4: R6-10.1186/bcr443.
Henderson BE, Ross RK, Judd HL, Krailo MD, Pike MC: Do regular ovulatory cycles increase breast cancer risk?. Cancer. 1985, 56: 1206-08. 10.1002/1097-0142(19850901)56:5<1206::AID-CNCR2820560541>3.0.CO;2-9.
Preston-Martin S, Pike MC, Ross RK, Henderson BE: Epidemiologic evidence for the increased cell proliferation model of carcinogenesis. Prog Clin Biol Res. 1991, 369: 21-34.
De Waard: Preventive intervention in breast cancer, but when?. Eur J Cancer Prev. 1992, 1: 395-99.
Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID, Rosen EM: BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science. 1999, 284: 1354-10.1126/science.284.5418.1354.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/7/75/prepub